95 related articles for article (PubMed ID: 8660839)
1. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia.
Veenstra H; Jacobs P; Dowdle EB
Cell Immunol; 1996 Jul; 171(1):68-73. PubMed ID: 8660839
[TBL] [Abstract][Full Text] [Related]
2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
3. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
4. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
5. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
Lamb CA; Cresswell P
J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
[TBL] [Abstract][Full Text] [Related]
6. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.
Roche PA; Marks MS; Cresswell P
Nature; 1991 Dec; 354(6352):392-4. PubMed ID: 1956401
[TBL] [Abstract][Full Text] [Related]
7. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
8. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
9. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
10. Complement C3b fragment covalently linked to tetanus toxin increases lysosomal sodium dodecyl sulfate-stable HLA-DR dimer production.
Serra VA; Cretin F; Pépin E; Gabert FM; Marche PN
Eur J Immunol; 1997 Oct; 27(10):2673-9. PubMed ID: 9368625
[TBL] [Abstract][Full Text] [Related]
11. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
12. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
13. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
Peterson M; Sant AJ
J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
[TBL] [Abstract][Full Text] [Related]
14. The nonpolymorphic MHC class II isotype, HLA-DQA2, is expressed on the surface of B lymphoblastoid cells.
Rudy GB; Lew AM
J Immunol; 1997 Mar; 158(5):2116-25. PubMed ID: 9036956
[TBL] [Abstract][Full Text] [Related]
15. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
Khalil H; Brunet A; Thibodeau J
J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
[TBL] [Abstract][Full Text] [Related]
16. MHC class II transport from lysosomal compartments to the cell surface is determined by stable peptide binding, but not by the cytosolic domains of the alpha- and beta-chains.
Théry C; Brachet V; Regnault A; Rescigno M; Ricciardi-Castagnoli P; Bonnerot C; Amigorena S
J Immunol; 1998 Sep; 161(5):2106-13. PubMed ID: 9725201
[TBL] [Abstract][Full Text] [Related]
17. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
18. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
19. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules.
Reber AJ; Turnquist HR; Thomas HJ; Lutz CT; Solheim JC
Immunogenetics; 2002 May; 54(2):74-81. PubMed ID: 12037599
[TBL] [Abstract][Full Text] [Related]
20. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.
Kropshofer H; Spindeldreher S; Röhn TA; Platania N; Grygar C; Daniel N; Wölpl A; Langen H; Horejsi V; Vogt AB
Nat Immunol; 2002 Jan; 3(1):61-8. PubMed ID: 11743588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
